A challenging task - Identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience.

Pauli, Chantal; Bochtler, Tilmann; Mileshkin, Linda; Baciarello, Giulia; Losa, Ferran; Ross, Jeffrey; Pentheroudakis, George; Zarkavelis, George; Yalcin, Suayib; Özgüroğlu, MUSTAFA; Beringer, Andreas; Scarato, Jeremy; Mueller-Ohldach, Mathis; Thomas, M; Moch, Holger; Krämer, Alwin

doi:10.1002/onco.13744

A challenging task - Identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience.

Pauli C., Bochtler T., Mileshkin L., Baciarello G., Losa F., Ross J. S., ...Daha Fazla

The oncologist, cilt.26, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 26
Basım Tarihi: 2021
Doi Numarası: 10.1002/onco.13744
Dergi Adı: The oncologist
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
Anahtar Kelimeler: Cancer of unknown primary, Diagnosis, Histology, Molecularly guided therapy, Comprehensive genomic profiling, Next&#8208, generation sequencing, PRIMARY SITE, BOSNIAK CLASSIFICATION, DIAGNOSIS, EXPRESSION, CARCINOMA, ORIGIN, NEOPLASMS, SPREAD
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background CUPISCO is an ongoing randomized phase II trial (NCT03498521) comparing molecularly guided therapy versus platinum-based chemotherapy in patients newly diagnosed with "unfavorable" cancer of unknown primary (CUP).